#USA #Chengdu #Windward Bio #SKB378 #Asmtha Treatment

Windward Bio's Exciting Progress in Asthma Treatment

In a significant milestone for asthma treatment, Windward Bio has reported positive interim results from the Phase 2 segment of its POLARIS-1 clinical trial, evaluating the efficacy of SKB378/WIN378. This innovative treatment aims to address the pressing needs of patients suffering from moderate-to-severe asthma, highlighting a promising new option in a market that has long sought advancements in therapy.

Trial Overview

The POLARIS-1 study, designed as an operationally seamless Phase 2/3 clinical trial, enrolled 147 patients with uncontrolled, moderate-to-severe asthma. The interim analysis focused on the initial cohort of 98 patients and yielded groundbreaking insights into the treatment's pharmacokinetics and efficacy. The results demonstrate not only significant improvement in lung functions, notably a mean increase in FEV1 (Forced Expiratory Volume in one second) of up to 174 ml, but also bear implications for potential long-term therapeutic strategies with twice-yearly dosing regimens.

Key Findings

The analysis showcased a sustained clinical effect through Week 24, after a single administration of SKB378/WIN378. Key biomarkers such as FeNO (fractional exhaled nitric oxide) and blood eosinophils also exhibited promising trends. Specific findings include:

• - Significant increases in FEV1: The placebo-adjusted mean increase reached 256 ml, demonstrating superior efficiency in lung function improvement.
• - Reduction in FeNO levels: Indicating a potential decrease in airway inflammation, showing a notable change of -43%.
• - Decrease in blood eosinophil counts: Up to a 51% reduction, further corroborating the treatment’s anti-inflammatory properties.

Safety and Tolerability

Importantly, SKB378/WIN378 demonstrated an excellent safety profile throughout the trial. Notably, there were no serious adverse events linked to the treatment, offering reassurance to patients and healthcare providers alike. Injection site reactions were minimal, with less than 1% experiencing complications, affirming the treatment's tolerability.

Next Steps and Phase 3 Initiatives

Given the encouraging results from the Phase 2 analysis, Windward Bio has initiated the first Phase 3 study targeting two twice-yearly doses of SKB378/WIN378. This next phase aims to further explore the treatment’s effects on asthma exacerbation rates and other critical efficacy metrics. Planning is also underway for a second Phase 3 trial, POLARIS-2, slated for the first half of 2027, providing further opportunities to validate these promising findings.

About SKB378/WIN378

SKB378/WIN378 stands out for its unique mechanism of action, targeting thymic stromal lymphopoietin (TSLP) to inhibit its signaling—an approach previously unutilized in asthma therapies. This fully human monoclonal antibody was designed for its long-acting potential, delivering sustained effects on lung function while aiming to improve patient compliance through less frequent dosing.

The collaborative development with Kelun-Biotech showcases a commitment to addressing unmet medical needs in asthma and potentially other respiratory conditions. As clinical trials progress, healthcare stakeholders remain optimistic about the broader implications of SKB378/WIN378 in improving asthma management.

Conclusion

As Windward Bio advances through its clinical development phases with SKB378/WIN378, the medical community’s anticipation grows. The interim results from the POLARIS-1 study indicate a significant step forward in the search for effective asthma therapies, paving the way for future innovations that promise to enhance patient quality of life.

For further updates on clinical results and future developments, stakeholders are encouraged to follow Windward Bio’s ongoing research initiatives.